Clinical Trials
69 trialsNCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT03442556 2025-06-12
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
University of Washington
Phase 2 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT05156905 2024-10-09
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
Phase 1 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT00176631 2023-12-22
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT03837353 2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Phase 1/2 Terminated
NCT04404140 2023-10-17
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
Phase 1 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00786682 2023-08-14
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT02516670 2023-06-07
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02565901 2021-10-01
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Phase 1/2 Terminated
NCT02985021 2021-08-05
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Seattle Institute for Biomedical and Clinical Research
Phase 2 Terminated
NCT02685267 2021-04-09
Doce/Enza
Prostate Cancer Clinical Trials Consortium
Phase 2 Terminated
NCT01194960 2020-10-19
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Oxford BioMedica
Phase 2 Terminated
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated
NCT03093272 2020-04-09
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated
NCT03043989 2020-02-17
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00582582 2019-12-13
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT01253642 2019-10-02
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00996502 2019-03-27
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Columbia University
Phase 1/2 Terminated
NCT02478125 2019-01-18
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02560051 2018-11-28
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02494713 2018-11-27
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00527124 2018-08-09
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02095717 2018-07-24
CURTAXEL
Centre Jean Perrin
Phase 2 Terminated
NCT00058448 2018-06-28
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)
SWOG Cancer Research Network
Phase 2 Terminated
NCT00096304 2018-04-10
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Medical University of South Carolina
Phase 1 Terminated
NCT00348816 2017-12-08
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT00480857 2017-10-06
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01145508 2017-09-19
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00482274 2017-04-28
Docetaxel in Treating Patients With Relapsed Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01155791 2017-03-15
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Stanford University
Phase 1 Terminated
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT00565227 2016-12-02
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT00861471 2016-06-30
Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00503984 2016-06-09
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
University of Miami
Phase 1/2 Terminated
NCT00024167 2016-03-22
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00448097 2016-03-17
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00450008 2016-03-17
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00521274 2016-03-17
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT01603420 2016-03-14
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
Phase 2/3 Terminated